BackgroundSPCs are granted for “products”. Products are defined as active ingredients or combinations of active ingredients (Art. 1(b) SPC Regulation). But what constitutes an active ingredient? The…
As far as the authors are aware, there is, as yet, no dedicated blog to plant varieties. Therefore the following post has been prepared for the Kluwer Patents Blog in the expectation that some of…
I reported last year on the three-part article series published in EPI Information by Tamaris Bucher, Principal Patent Attorney at Novartis, on the EPO’s approach to assessing inventive step for…
Preliminary injunctions (“PIs”) matter in life sciences patent cases. As often as not, the party which prevails at this stage of the litigation will have the upper hand in settlement negotiations. …
The final week of July usually produces a flurry, and sometimes an avalanche, of decisions from the English Courts as Judges attempt to clear their desks before the holiday period. This year was no…
This year, at the Annual Fordham IP Law & Policy Conference, we heard Lord Justice Birss reflect on how we are living through a transformative era in intellectual property (IP) law. In the age of…
Tempus fugit. It’s hard to believe that the UPC opened for business over two years ago and, after a relatively slow start, is now flourishing. It would be fair to say that, with certain notable…
As is well known in the life sciences community in Europe, both the Commission and the Parliament have proposed reforms to the Medicines Directive which, if implemented, would serve to broaden the…
On 9 January 2025 I reported on Parts 1 and 2 of a three-part article in EPI Information by Tamaris Bucher, a Principal Patent Attorney at Novartis Pharma AG, on the current approach to antibody…
